Aisling Capital Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding EPRX
Aisling Capital Management's EPRX Position: Q3 2026 in Review
Aisling Capital Management held its Eupraxia Pharmaceuticals (EPRX) position steady in Q3 2026 at 325,000 shares worth $2.96M. The position accounts for 0.99% of the portfolio, ranked #8.
Aisling Capital Management first reported a position in EPRX in Q1 2026 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.
- Aisling Capital Management held 325,000 shares of Eupraxia Pharmaceuticals worth $2.96M as of Q3 2026.
- Aisling Capital Management left its Eupraxia Pharmaceuticals share count unchanged in Q3 2026.
- Eupraxia Pharmaceuticals made up 0.99% of Aisling Capital Management's portfolio in Q3 2026, its #8 holding.
- Aisling Capital Management first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.
Based on Aisling Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.